Beranda › Penyakit Paru Interstisial
Uji klinis Penyakit Paru Interstisial yang merekrut di AS
54 studi untuk Penyakit Paru Interstisial merekrut peserta di lokasi di seluruh Amerika Serikat.
Kota dengan studi terbanyak
- New York City, NY19 studi
- Philadelphia, PA17 studi
- Los Angeles, CA15 studi
- Kansas City, KS14 studi
- Charleston, SC13 studi
- Durham, NC13 studi
- Houston, TX13 studi
- Chicago, IL13 studi
- Aurora, CO11 studi
- Ann Arbor, MI11 studi
- Birmingham, AL10 studi
- Salt Lake City, UT10 studi
- Rochester, MN10 studi
- Boston, MA10 studi
- Minneapolis, MN9 studi
- Phoenix, AZ9 studi
- Dallas, TX9 studi
- Orlando, FL9 studi
- Cincinnati, OH8 studi
- Tampa, FL8 studi
- Denver, CO7 studi
- Bend, OR7 studi
- San Francisco, CA7 studi
- Indianapolis, IN6 studi
- Pittsburgh, PA6 studi
- Winston-Salem, NC6 studi
- Richmond, VA6 studi
- Washington, DC6 studi
- New Haven, CT5 studi
- Miami, FL5 studi
- Scottsdale, AZ5 studi
- Nashville, TN5 studi
- Albuquerque, NM5 studi
- Columbus, OH5 studi
- Jacksonville, FL5 studi
- Naples, FL5 studi
- Gainesville, FL5 studi
- Oklahoma City, OK5 studi
- Cleveland, OH5 studi
- Davie, FL4 studi
Berdasarkan negara bagian
- Alabama10 studi
- Arizona14 studi
- California23 studi
- Colorado16 studi
- Connecticut5 studi
- Distrik Columbia5 studi
- Florida25 studi
- Georgia4 studi
- Illinois13 studi
- Indiana6 studi
- Kansas14 studi
- Kentucky4 studi
- Louisiana5 studi
- Maryland5 studi
- Massachusetts12 studi
- Michigan16 studi
- Minnesota15 studi
- Mississippi3 studi
- Missouri6 studi
- Nebraska3 studi
- Nevada4 studi
- New Jersey3 studi
- New Mexico5 studi
- New York21 studi
- North Carolina19 studi
- Ohio14 studi
- Oklahoma5 studi
- Oregon9 studi
- Pennsylvania19 studi
- South Carolina14 studi
- Tennessee7 studi
- Texas19 studi
- Utah10 studi
- Virginia8 studi
- West Virginia3 studi
- Wisconsin5 studi
Studi yang baru diperbarui
Teks studi resmi (Bahasa Inggris)
FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT07540988A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
Menerima pesertaFase 3
Usia 40 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT07201922Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT07179380LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Menerima pesertaFase 2
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT05798923Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging
Menerima pesertaFase 3
Usia 18 hingga 100 · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT07613099Pulmonary Fibrosis Foundation Community Registry
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT05382572A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT06806592A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT07323732SUPPORT-T in Patients With Progressive Pulmonary Fibrosis and Their Caregivers
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT07269262A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier)
Menerima pesertaFase 3
Usia 18 hingga 85 · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT07816185A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT06716606A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
Menerima pesertaFase 2/3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT05878717A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT06572384Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease
Menerima pesertaFase 2
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT07473700A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
Menerima pesertaFase 2
Usia 40 ke atas · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT06968845Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT06911632A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
Menerima pesertaFase 2
Usia 18 hingga 85 · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT07333183A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
Menerima pesertaFase 3
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT07285655Dorothy P. and Richard P. Simmons Center for ILD Research Registry
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 27 Agu 2026 · NCT00258583DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 26 Agu 2026 · NCT06388421Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT07486869Platform Clinical Study for Conquering Scleroderma
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Agu 2026 · NCT06195072PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis
Menerima pesertaStudi observasional
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 18 Agu 2026 · NCT06855329RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
Menerima pesertaFase 2/3
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT06328777Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
Menerima pesertaFase 2
Usia 8 hingga 60 · Semua jenis kelamin · Diperbarui 14 Agu 2026 · NCT03630211Dari ClinicalTrials.gov, data diambil 2 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.